Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC: Durvalumab after concurrent chemoradiation in unresectable stage III non-small cell lung cancer
2014-000336-42Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2014
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab arm with Placebo arm (2 arms). Primary endpoints: Progression-free survival (PFS) and Overall survival (OS). Started May 2014; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-000336-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000336-42.